Latest Headlines

Latest Headlines

Novartis faces probes on Tekturna tactics, Iran sales

Novartis may be looking at another trial of its troubled blood pressure drug Tekturna. This would not be a clinical trial, however, but more of the civil or criminal kind.

Which FiercePharma news attracts the most readers online?

As anyone in pharma knows, data can be a wonderful thing. Crunching data can also be addictive, like kettle corn or tortilla chips. We here at FierceMarkets can spend hours consuming statistics about our readers and web traffic. Here are the stories that garnered the most web traffic over the past 12 months. More >>

Indian panel accuses Big Pharma of colluding with regulators

An Indian government report has hit the domestic pharma business like a whirlwind--and sucked Big Pharma into the fury.

Novartis to revamp Rasilez label with safety risks

The data on Rasilez 's safety risks is coming home to roost. The Novartis ($NVS) blood-pressure drug will get a new warning in Europe at regulators' request, after a recent trial flagged links...

Novartis ends Tekturna trial on safety concerns

Bad news for Novartis' ($NVS) blood pressure med Tekturna (aka Rasilez). The drug company has decided to end a trial evaluating the med in Type 2 diabetes patients with renal impairment who are also

Blockbuster hopes for Rasilez fade at Novartis

Novartis' ($NVS) bid to expand the use of Rasilez has run into serious trouble. The pharma company joined the lineup of Big Pharma companies reporting trial setbacks today with the news that

FDA approves Novartis' combo pill Teklamo

The FDA has approved Teklamo, a high blood pressure medication that combines Tekturna with the calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely

Novartis: Tekturna doesn't help after heart attack

Novartis will not pursue an outcomes trial of its high blood pressure med Tekturna (aliskiren) in combination with standard therapy for heart attack patients after the drug failed to demonstrate a

Novartis buying Speedel for $880 million

Switzerland's Novartis has scooped up a majority of the shares of Speedel and plans to swiftly complete the purchase of all its stock in a deal valued at $880 million. At 130 francs per share,

ALSO NOTED: BMS to shutter Puerto Rico plant; Ranbaxy can launch copycat Imitrex;

> Bristol-Myers Squibb will close its plant in Barceloneta, Puerto Rico, as part of its ongoing restructuring efforts. About 225 people will lose their jobs with the closure.